Announcements Trials
Browse Landscape

Phase

Phase 3 5Phase 2 4Phase 4 3Phase NA 2Phase 1/2 1Phase 1 1

Status

Terminated 2Completed 2

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 1

Conditions

Breast Neoplasms 870Carcinoma, Non-Small-Cell Lung 637Prostatic Neoplasms 516Multiple Myeloma 443Neoplasms 425Leukemia, Myeloid, Acute 380Lymphoma 357Melanoma 335Leukemia 335Neoplasm Metastasis 322Lung Neoplasms 308Lymphoma, Non-Hodgkin 303Leukemia, Lymphocytic, Chronic, B-Cell 301Colorectal Neoplasms 282Ovarian Neoplasms 266Pancreatic Neoplasms 249Precursor Cell Lymphoblastic Leukemia-Lymphoma 241Recurrence 240Myelodysplastic Syndromes 233Glioblastoma 212Hodgkin Disease 201Lymphoma, Large B-Cell, Diffuse 197Lymphoma, Follicular 195Brain Neoplasms 195Carcinoma, Renal Cell 190Head and Neck Neoplasms 188Squamous Cell Carcinoma of Head and Neck 186Lymphoma, Mantle-Cell 171Sarcoma 158Fallopian Tube Neoplasms 139

Interventions

MEDI2070 2secukinumab 1Vaccines 1Saline Solution 1Herpes Zoster Vaccine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Has results × Crohn Disease × Clear all
NCT02538341 2021-11-23

Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial)

University of Alabama at Birmingham

Phase 2 Completed
617 enrolled 17 charts

Arthritis, Arthritis, Rheumatoid, Crohn Disease, Psoriasis, Spondylitis, Ankylosing, Arthritis, Psoriatic

NCT01714726 2021-05-26

Evaluation of Efficacy and Safety of MEDI2070 in Patients With Active, Moderate-to-severe Crohn's Disease.

AstraZeneca

Phase 2 Completed
121 enrolled 22 charts

Crohn Disease, Inflammatory Bowel Diseases

NCT02574637 2021-05-26

Evaluation of Efficacy and Safety of Brazikumab (MEDI2070) in Participants With Active, Moderate to Severe Crohn's Disease

AstraZeneca

Phase 2 Terminated
29 enrolled 25 charts

Crohn Disease, Inflammatory Bowel Diseases

NCT00584740 2015-03-31

Efficacy, Safety and Tolerability of AIN457 in Moderate to Severe Active Crohn's Disease

Novartis

Phase 2 Terminated
59 enrolled 13 charts
Lymphoid

Crohn Disease, Lymphoma, Follicular, Motor Activity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡